

# Pneumococcal acute otitis media aom biology essay

[Science](#), [Biology](#)



**ASSIGN  
BUSTER**

Journal: IJID Please e-mail or fax your responses and any corrections to: E-mail: corrections.eseo@elsevier.thomsondigital.com Article Number: 1656 Fax: +353 6170 9272 Dear Author, Please check your proof carefully and mark all corrections at the appropriate place in the proof (e. g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours. For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>. Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the ' Q ' link to go to the location in the proof.

**Location in Query / Remark: click on the Q link to go  
article Please insert your reply or correction at the  
corresponding line in the proof**

Q1 Please confirm that given names and surnames have been identified correctly. Q2 Please provide an e-mail address for correspondence purposes. Please check this box or indicate your approval if you have no corrections to make to the PDF file Thank you for your assistance. 12 Pneumococcal acute otitis media in infants and children in central 3 Romania, 2009–2011: microbiological characteristics and potential 4 coverage by pneumococcal conjugate vaccines 5 O. Falup-Pecurariu Q1a, E. Leibovitz b,\* , A. Mercas a, L. Bleotu a, C. Zavarache a, N. Porat b, 6 R. Dagan b, D. Greenberg b 7 a Department of Pediatrics, Children's Hospital, Faculty of Medicine, Transilvania University, Brasov, Romania 8 b Pediatric Infectious Disease Unit,

<https://assignbuster.com/pneumococcal-acute-otitis-media-aom-biology-essay/>

Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel

Q291011 1. Introduction12 Acute otitis media (AOM) is the most frequent bacterial disease13 of childhood, affecting millions of children worldwide and14 remaining a major public health problem. 1-3 The most common15 causative agents in AOM are *Streptococcus pneumoniae*, non-16 typeable *Haemophilus influenzae* (NTHi), *Moraxella catarrhalis*, and17 *Streptococcus pyogenes*. 4-8 Together, *S. pneumoniae* and NTHi18 account for 60-80% of the AOM pathogens. 9 Antibiotic resistance19 is high in pneumococcal AOM, with penicillin- and amoxicillin-20 non-susceptible strains accounting for 30-70% of cases. 10-16 The21 most commonly encountered *S. pneumoniae* serotypes in AOM are22 6A, 6B, 14, 19A, 19F, and 23F. 15, 16 The highest antibiotic non-23 susceptibility is found in vaccine serotypes 6A, 6B, 9 V, 14, 19A, 24 19F, and 23F. 11, 12, 15, 1625 Information on antibiotic resistance patterns and serotype26 distribution of *S. pneumoniae* isolates in infants and young children27 in Romania is limited. In a multinational study, 42% of28 *S. pneumoniae* AOM isolates from Romania were intermediately29 or fully resistant to penicillin. 17 In three studies investigating30 pneumococcal mucosal and invasive disease isolates inInternational Journal of Infectious Diseases xxx (2013) xxx. e1-xxx. 5A R T I C L E I N F OArticle history:

Received 23 November 2012Received in revised form 26 December

2012Accepted 2 February 2013Corresponding Editor: Eskild Petersen,

Aarhus, DenmarkKeywords: Acute otitis media*Streptococcus*

*pneumoniae*Antibiotic resistanceChildrenS U M M A R YObjective: To assess the epidemiological and microbiological characteristics of pneumococcal acute otitis media (AOM) in children in Brasov, Central Romania, before the

introduction of pneumococcal conjugate vaccine (PCV) into the routine national immunization program. Methods: All AOM patients aged <5 years who underwent tympanocentesis or presented with purulent otorrhea of  $\geq 24$  h duration during 2009–2011 were enrolled. Results: Two hundred and twelve consecutive AOM patients had a middle ear fluid (MEF) culture performed; 99 (46.6%) episodes occurred in patients <12 months of age. One hundred and eleven (52.4%) episodes were culture-positive. Tympanocentesis was performed in 142 patients and spontaneous otorrhea cultures in 70 patients. Overall, 114 pathogens were recovered: *Streptococcus pneumoniae* was the most common isolate (81 isolates, 70.3% of all culture-positive episodes), followed by non-typeable *Haemophilus influenzae* (26, 20.7%), *Streptococcus pyogenes* (5, 4.5%), and *Moraxella catarrhalis* (2, 1.8%). Antibiotic susceptibility and serotyping were performed for 48 (59.3%) *S. pneumoniae* isolates: 45 (93.8%) were non-susceptible to penicillin (minimal inhibitory concentration (MIC)  $\geq 2.0$  mg/ml in 24, 53.3%) and 37 (77.1%) isolates had ceftriaxone MIC values  $\geq 0.5$  mg/ml (16 with MIC  $> 2.0$  mg/ml). *S. pneumoniae* non-susceptibility rates to trimethoprim-sulfamethoxazole, erythromycin, and clindamycin were 75.0%, 58.3%, and 35.4%, respectively. All isolates were susceptible to chloramphenicol. Multidrug resistance was found in 33 (68.7%) isolates. The most common *S. pneumoniae* serotypes were 19F (14, 29.2%), 6B (8, 16.7%), 23F (8, 16.7%), and 14 (6, 12.5%). Serotype 19A was found in three (6.2%) patients and 6A in two (4.1%). Non-PCV13 serotypes represented six (12.6%) of all serotypes (four of them non-susceptible to penicillin). Thirty-six (75.0%) isolates were potentially covered by PCV7, 37 (77.0%) by PCV10,

and 42 (87.5%) by PCV13. Conclusions: (1) *S. pneumoniae* was the most prevalent pathogen, with frequent antibiotic resistance and multi-resistance patterns; (2) most pneumococcal AOM and multidrug-resistant episodes could be prevented by PCVs. © 2013 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.\* Corresponding author. G Model IJID 1656 1-5 Please cite this article in press as: Falup-Pecurariu O, et al. Pneumococcal acute otitis media in infants and children in central Romania, 2009–2011: microbiological characteristics and potential coverage by pneumococcal conjugate vaccines. *Int J Infect Dis* (2013), <http://dx.doi.org/10.1016/j.ijid.2013.02.002> Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: [www.elsevier.com/locate/ijid](http://www.elsevier.com/locate/ijid) 1201-9712/\$36.00 – see front matter © 2013 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. <http://dx.doi.org/10.1016/j.ijid.2013.02.002> 31 HIV-negative and HIV-positive infants and children in northeast-central Romania, high rates of recovery of serotypes 19A and 23F and 33 of multidrug-resistant (MDR) organisms were reported. 18–20 34 Recently, high rates of colonization with *S. pneumoniae* (reaching 35 71% in children 13–24 months of age) accompanied by high 36 resistance rates to most of the commonly used antibiotic drugs 37 were reported among healthy and sick infants and children 38 <5 years old in central Romania. 21 39 Active and continuous surveillance of the microbiology and 40 antibiotic susceptibility patterns of AOM pathogens in Romania is 41 important, particularly during the period preceding the introduction of pneumococcal conjugate vaccine (PCV). The aims of the 43 present study were to assess: (1) the overall distribution

of 44 otopathogens and their antibiotic resistance patterns; and (2) PCV45 coverage of *S. pneumoniae* middle ear fluid (MEF) isolates in Brasov, 46 central Romania, during 2009–2011. 47

## 2. Patients and methods

48 We conducted a prospective epidemiological study between 49 January 1, 2009 and December 31, 2011, at the Children’s Hospital 50 of Brasov, in the central part of Romania. Brasov has a population of 51 400 000 inhabitants and the hospital is the only medical center 52 providing medical care for infants and children in the city. The 53 study protocol was approved by the institutional review board of 54 the University of Transilvania, Brasov. Informed consent was 55 obtained from the legal guardians of all children. 56

### 2. 1. Patients and procedures

57 The study patients were infants and children aged <5 years 58 diagnosed with AOM by a pediatrician, family physician, or 59 otolaryngologist. The diagnosis was done when the patients 60 presented with: (1) symptoms and physical findings consistent 61 with AOM (fever, irritability, tugging of the ear, and redness and 62 bulging of the tympanic membrane with blurring of its anatomic 63 landmarks); (2) acute illness lasting  $\geq$  7 days. Bulging of the 64 tympanic membrane (in addition to clinical symptoms of AOM) 65 was present in all cases where a tympanocentesis was performed. 66 Culture specimens were obtained by either tympanocentesis or 67 collection of pus from draining the ears (if lasting  $\geq$  24 h before 68 enrollment). Patients with tympanostomy tubes were excluded 69 from the study. In all episodes, we collected information on the 70 patient’s age, sex, and ethnicity, the type of specimen (tympano- 71 centesis or draining pus), and the patient’s AOM history and recent 72 antibiotic treatment. Data were obtained from the medical records 73 of the

hospital, clinical medical chart, or parent interview. None of 74 the patients had been immunized with a PCV before enrollment. 75 Tympanocentesis was performed by the study otolaryngologist<sup>76</sup> (AM) as previously described. 7, 1277 2. 2. Bacteriology<sup>78</sup> Swabs of MEF aspirates were placed in MW173 Amies transport<sup>79</sup> medium (Transwab; Medical Wire and Equipment), plated<sup>80</sup> immediately on trypticase agar containing 5% sheep blood and<sup>81</sup> 5 mg/ml gentamicin, and on chocolate agar, and incubated at 35 °C<sup>82</sup> for 48 h in a 5% enriched CO<sub>2</sub> atmosphere. Identification, <sup>83</sup> serotyping, and testing of antimicrobial susceptibility to penicillin<sup>84</sup> and ceftriaxone (by E-test, PDM Epsilon meter, AB Biodisk, Solna, <sup>85</sup> Sweden) and erythromycin, clindamycin, chloramphenicol, and<sup>86</sup> trimethoprim-sulfamethoxazole (TMP-SMX) (by disk diffusion)<sup>87</sup> were performed as described elsewhere, in accordance with the<sup>88</sup> Clinical and Laboratory Standards Institute (CLSI) recommenda-<sup>89</sup> tions. 22 Non-susceptibility to <sub>3</sub> antibiotic classes was considered<sup>90</sup> multidrug resistance (MDR). Serotyping was done by quellung<sup>91</sup> reaction. 23 The organisms were sub-cultured and stored at <sub>70</sub> °C<sup>92</sup> at the Microbiology Laboratory of the Children' Hospital of Brasov<sup>93</sup> and were further transported by air to the Pediatric Infectious<sup>94</sup> Disease Unit Laboratory of the Soroka University Medical Center, <sup>95</sup> Beer-Sheva, Israel, where all antimicrobial susceptibility testing<sup>96</sup> and serotyping was carried out. <sup>97</sup> S. pneumoniae isolates were considered susceptible to penicillin<sup>98</sup> if the minimal inhibitory concentration (MIC) values were<sup>99</sup> <sub>0.06</sub> mg/ml, intermediate if penicillin MIC values were between<sup>100</sup> 0.125 mg/ml and 1.0 mg/ml, and resistant if MIC values were<sup>101</sup> <sub>2.0</sub> mg/ml. Ceftriaxone intermediate resistance was defined by<sup>102</sup> MICs values between 0.5 and 1.

0 mg/ml, and high resistance by 103 MICs values > 2.0 mg/ml. 104 2. 3. Statistical analysis 105 Data were recorded using Microsoft Access office software. The 106 statistical analysis was performed using SPSS 17.0 software. 107 Contingency table analysis for comparing rates between un- 108 matched samples was performed using the Chi-square test or 109 Fisher's exact test, as appropriate. The Student independent 110 samples t-test was used to compare continuous variables. The 111 percentages of serotype coverage were calculated and compared 112 between PCV7 (serotypes 4, 6B, 9 V, 14, 18C, 19F, and 23F), PCV10 113 (PCV7 plus serotypes 1, 5, and 7F), and PCV13 (PCV10 plus 114 additional serotypes 3, 6A, and 19A). All tests were considered 115 significant if p-values were <0.05. 116 3. Results 117 During the study period, 212 consecutive infants and young 118 children <5 years of age were enrolled. There were 120 (56.6%) 119 males. The mean age ( $\pm$  standard deviation) was 18.0  $\pm$  14.2 months. 120 Ninety-nine (46.6%) episodes occurred in patients <12 months old 121 and 136 (64.2%) episodes occurred in children <2 years old. One 122 hundred and eleven samples (52.4%) were culture-positive. Children 123 with culture-positive MEF were older than children with culture- 124 negative MEF (20.6  $\pm$  15.2 months vs. 15.4  $\pm$  12.6 months,  $p = 0.008$ ). 125 Tympanocentesis was recorded in 142 patients and spontane- 126 ous otorrhea in 70 patients. No differences were recorded in the 127 proportions of spontaneous perforation between children with 128 culture-positive and children with culture-negative MEF (38/111, 129 34.2% vs. 32/101, 31.7%,  $p = 0.7$ ). 130 A total of 114 isolates (76 from tympanocentesis and 38 from 131 spontaneous otorrhea specimens) were recovered. S.



pneumoniae<sup>132</sup> was the most common isolate (81 isolates, 78 episodes, 71.1% of all 133 pathogens recovered and 70.3% of all culture-positive episodes), 134 followed by NTHi (26, 23; 22.8% and 20.7%), Streptococcus<sup>135</sup> pyogenes (5, 5; 4.4% and 4.5%) and Moraxella catarrhalis (2, 2; 1.8% and 1.8%) (Table 1). In three patients (1.4% of all episodes), 137 both *S. pneumoniae* and NTHi were isolated. No differences were<sup>138</sup> recorded in the percentages of *S. pneumoniae* recovered from Table 1 Acute otitis media microbiology of 212 episodes (111 culture-positive) during 2009–2011 Pathogen No. of episodes a Streptococcus pneumoniae 78 (70.3) Haemophilus influenzae 23 (20.7) Streptococcus pyogenes 5 (4.5) Moraxella catarrhalis 2 (1.8) *S. pneumoniae* + *H. influenzae* 3 (2.7) Culture-positive 111 Culture-negative 101 Total 212 a The percentage of all culture-positive episodes is given in parenthesis. O. Falup-Pecurariu et al. / International Journal of Infectious Diseases xxx (2013) xxx. e1–xxx. e5 e2 G Modell JID 1656 1–5 Please cite this article in press as: Falup-Pecurariu O, et al. Pneumococcal acute otitis media in infants and children in central Romania, 2009–2011: microbiological characteristics and potential coverage by pneumococcal conjugate vaccines. Int J Infect Dis (2013), <http://dx.doi.org/10.1016/j.ijid.2013.02.002> 139 tympanocentesis compared with those isolated from spontaneous otorrhea (55/76, 72.4% vs. 26/38, 68.4%,  $p = 0.7$ ). No<sup>141</sup> differences were recorded in the mean age at diagnosis of<sup>142</sup> patients with *S. pneumoniae* AOM compared with patients with<sup>143</sup> AOM caused by other etiologic agents (18.16 ± 7.08 vs. 14.42 ± 18.37 months,  $p = 0.1$ ).<sup>145</sup> Reliable information on prior antibiotic treatment (during the<sup>146</sup> 24 h preceding AOM diagnosis) was available for 68/111 (60.

2%)<sup>147</sup> culture-positive patients; 29/68 (42. 6%) culture-positive patients<sup>148</sup> received previous antibiotic treatment compared with 34/101<sup>149</sup> (33. 7%) culture-negative patients ( $p = 0. 24$ ). The representation of<sup>150</sup> *S. pneumoniae* was higher in patients previously untreated with<sup>151</sup> antibiotics compared with patients treated with antibiotics (28/39, <sup>152</sup> 71. 7% vs. 14/29, 48. 3%,  $p = 0. 03$ ). <sup>153</sup> Antibiotic susceptibility testing and serotyping were performed<sup>154</sup> for 48/81 (59. 3%) *S. pneumoniae* isolates. Forty-five (93. 8%)<sup>155</sup> *S. pneumoniae* isolates were non-susceptible to penicillin; <sup>24</sup>156 (53. 3%) had MIC values  $\geq 2. 0$  mg/ml. Six isolates had a penicillin<sup>157</sup> MIC value of 16. 0 mg/ml, one had a MIC of 8. 0 mg/ml, and three had<sup>158</sup> a MIC of 4. 0 mg/ml. Thirty-seven (77. 1%) isolates had ceftriaxone<sup>159</sup> MIC values  $\geq 0. 5$  mg/ml (32. 0 mg/ml for five isolates, 4. 0 mg/ml for<sup>160</sup> nine isolates, 2. 0 mg/ml for one isolate, and 1. 0 mg/ml for one<sup>161</sup> isolate). The non-susceptibility rates to TMP-SMX, erythromycin, <sup>162</sup> and clindamycin were 36/48 (75%), 28/48 (58. 3%), and 17/48<sup>163</sup> (35. 4%), respectively. All isolates were susceptible to chloram-<sup>164</sup>phenicol. Resistance to  $\geq 1$  antibiotic class was found in 44 (91. 7%)<sup>165</sup> and MDR in 33 (68. 7%) *S. pneumoniae* isolates. No differences were<sup>166</sup> recorded in the resistance patterns to antibiotics of *S. pneumoniae*<sup>167</sup> recovered from tympanocentesis versus the isolates recovered<sup>168</sup> from culture of spontaneous otorrhea. <sup>169</sup> The most common *S. pneumoniae* serotypes were: 19F (14, <sup>170</sup> 29. 2%), 6B (8, 16. 7%), 23F (8, 16. 7%), and 14 (6, 12. 5%) (Table 2). <sup>171</sup> Serotype 19A was found in three (6. 2%) patients and 6A in two (4. 1%)<sup>172</sup> patients. The non-PCV13 serotypes represented six (12. 6%) of all<sup>173</sup> serotypes, and four of them were non-susceptible to penicillin. Six<sup>174</sup> (75%) of the eight serotype

23F isolates had a penicillin MIC of 16.0 mg/ml and a ceftriaxone MIC value of 32.0 mg/ml; 3/14 (21.4%) serotype 19F isolates had a penicillin MIC value of 4.0 mg/ml and one had a penicillin MIC value of 8.0 mg/ml. The MDR isolates included, in descending order, serotypes 19F, 6B, 23F, 19A, and 6A. Of the 14 serotype 19F isolates, 13 (92.9%) were non-susceptible to penicillin, erythromycin, and TMP-SMX, and 9/13 (69.1%) also to clindamycin. All eight serotype 6B isolates were non-susceptible to penicillin, erythromycin, TMP-SMX, and clindamycin. All eight serotype 23F isolates were non-susceptible to penicillin, erythromycin, and TMP-SMX, and 5/8 (62.5%) also to clindamycin. All three serotype 19A isolates were non-susceptible to penicillin, erythromycin, and TMP-SMX, and 2/3 (66.7%) also to clindamycin. One of the two serotype 6A isolates was non-susceptible to penicillin, erythromycin, TMP-SMX, and clindamycin. Of the 48 tested *S. pneumoniae* serotype isolates, 36 (75.0%) are included in PCV7, 37 (77.0%) in PCV10, and 42 (87.5%) in PCV13.

4. Discussion

The present study aimed to provide baseline data on the contribution of *S. pneumoniae* to the etiology of AOM in Romania. We also analyzed the resistance patterns to antibiotics and the serotype distribution of this pathogen before the introduction of universal PCV immunization in Romania. Our main findings were: (1) infants and young children with culture-positive AOM were older compared with those with culture-negative AOM; (2) *S. pneumoniae* was the dominant etiologic agent, being isolated in 74.3% of the culture-positive patients; (3) most of the isolates were resistant to penicillin, erythromycin, and TMP-SMX, and MDR was very common; (4) the

current PCVs could potentially prevent most of the 205 pneumococcal AOM in the region. The present study may 206 provide a basis for follow-up and monitoring of AOM etiology 207 and resistance patterns after the introduction of PCV into the 208 national program. 209 In the Brasov area, we recently reported that of 205 210 pneumococcal nasopharyngeal isolates obtained from infants 211 and children <5 years of age (attending daycare centers, 212 immunization clinics, or visiting the pediatric emergency room 213 of the hospital for different acute illnesses, as well as healthy 214 patients admitted to the surgery department for elective 215 procedures), 83% were non-susceptible to penicillin and 18% 216 were non-susceptible to ceftriaxone, of which 40.5% and 16% were 217 highly-resistant to penicillin and ceftriaxone, respectively. 21 The 218 non-susceptibility rates to erythromycin, TMP-SMX, tetracycline, 219 and clindamycin were also high (> 50% for each antibiotic) and 220 MDR was found in 67% of isolates. The most common pneumo- 221 coccal serotypes isolated were 23F, 6B, 19F, 14, 6A, and 19A, and 222 the potential coverage by PCV7, PCV10, and PCV13 was 66%, 74%, 223 and 80%, respectively. This is consistent with the AOM findings in 224 the current study. 225 The major limitation of this study derives from the small 226 number of pneumococcal isolates evaluable for antibiotic 227 susceptibility testing and serotyping. On the other hand, the data 228 presented here from MEF cultures performed in AOM patients 229 diagnosed and treated at the Brasov Children's Hospital are 230 additional to previously published information on the pneumo- 231 coccal carriage in patients enrolled from daycare centers and 232 immunization clinics in the city of Brasov and also from the 233 emergency room and surgery department of the hospital (which

is<sup>234</sup> the only referral pediatric hospital in the whole area and is the<sup>235</sup> only site where MEF and nasopharyngeal cultures are per-<sup>236</sup> formed). 21

Therefore, we are convinced that these two studies<sup>237</sup> from Brasov provide an up-to-date and reliable picture of the local<sup>238</sup> pneumococcal burden in infants and young children and the<sup>239</sup> antibiotic susceptibility, serotype distribution, and potential<sup>240</sup> serotype coverage by PCVs in the city of

Brasov and the<sup>241</sup> surrounding areas. At the present time, additional limited data<sup>242</sup> from nasopharyngeal and MEF pneumococcal isolates obtained<sup>243</sup>

from infants and young children are available from the<sup>244</sup> northeastern (Iasi) and southern (Bucharest) areas of the country<sup>245</sup> and provide a similar picture in terms of colonization burden, <sup>246</sup> extremely high antibiotic

resistance rates, serotype distribution, <sup>247</sup> and potential PCV coverage. 17-

21, <sup>248</sup> The presented data, together with the additional data from<sup>249</sup>

northeastern Romania, raise major concerns regarding the<sup>250</sup> unskilled use of antibiotics in this country, leading to high

Table 2 Streptococcus pneumoniae serotype distribution (in decreasing frequency) for 48 acute

otitis media episodes

Serotype	No. episodes	(%)	MDR
19F	14	(29.2)	13 (92.9%)
23F	8	(16.7)	8 (100%)
6B	8	(16.7)	8 (100%)
14	6	(12.5)	-
19A	3	(6.2)	3 (100%)
6A	2	(4.1)	1 (50%)
22F	2	(4.1)	-
9V	1	(2.1)	-
34	1	(2.1)	-
9A	1	(2.1)	-
7F	1	(2.1)	-
Omni-negative	1	(2.1)	-
Total	48	33 (68.7%)	

MDR, multiple drug resistance. O. Falup-Pecurariu et al. / International Journal of Infectious

Diseases xxx (2013) xxx. e1-xxx. e5 e3G Model IJID 1656 1-5 Please cite this

article in press as: Falup-Pecurariu O, et al. Pneumococcal acute otitis media

in infants and children in central Romania, 2009-2011: microbiological

characteristics and potential coverage by pneumococcal conjugate vaccines.

https://assignbuster.com/pneumococcal-acute-otitis-media-aom-biology-essay/

Int J Infect Dis (2013), <http://dx.doi.org/10.1016/j.ijid.2013.02.002>

resistance. Furthermore, the high rate of resistance is of concern in terms of the efficacy of current antimicrobial agents in the treatment of AOM. Faced with the alarming resistance data presented in this study, an intervention program including a major reduction in antibiotic use, combined with introduction of routine vaccination with PCVs, is much needed in Romania. In France, Cohen et al. clearly showed that the implementation of a national program of reduction of inappropriate antibiotic use markedly contributed to the efficacy of PCV7 in reducing the carriage of penicillin-non-susceptible pneumococci in children with AOM. In a study evaluating the association between antibiotic use in the community and the increase in antibiotic-resistant *S. pneumoniae* carriage in Bedouin children aged <5 years in southern Israel from 1998 to 2005, Greenberg et al. examined all the antibiotic prescriptions provided from two community primary pediatric clinics and reported a decrease by 19% in the total annual prescription rates, mainly as a result of a reduction in amoxicillin-clavulanate prescriptions. Oral cephalosporins, erythromycin, and penicillin prescription rates decreased significantly as well, but azithromycin prescription rates increased significantly during the study period. In parallel, the authors analyzed the *S. pneumoniae* nasopharyngeal carriage in healthy children <5 years old from the same communities and were able to demonstrate an increase in the proportion of nasopharyngeal *S. pneumoniae* with penicillin MICs  $\geq 1.0$  mg/ml from 8% to 21% and significant increases in resistance to clindamycin, erythromycin, and

tetracycline and also in multidrug resistance. The authors<sup>279</sup> suggested an association between the increased carriage of MDR<sup>280</sup> *S. pneumoniae* and the increased azithromycin consumption, and<sup>281</sup> cautioned that a reduction in the total antibiotic use may not be<sup>282</sup> sufficient as long as antibiotics with a high potential for the<sup>283</sup> promotion of multidrug resistance, like azithromycin, continue to<sup>284</sup> be used widely. <sup>26</sup><sup>285</sup> The introduction of the 7-valent conjugate PCV (PCV7)<sup>286</sup> had a major role in the reduction of invasive and mucosal<sup>287</sup> disease rates caused by *S. pneumoniae* and of the antimicrobial<sup>288</sup> resistance of the isolated organisms, and also, although less<sup>289</sup> impressive, in the reduction of nasopharyngeal colonization<sup>290</sup> and AOM cases caused by this pathogen. <sup>27-32</sup> In our study, the<sup>291</sup> good coverage of overall pneumococcal serotypes and also of<sup>292</sup> MDR pneumococcal isolates by all PCVs, and in particular by<sup>293</sup> PCV13 (87. 5% and 100%, respectively), are important and<sup>294</sup> encouraging findings. <sup>295</sup> PCV7 was registered in Romania in September 2007, but is not<sup>296</sup> yet included in the routine immunization program for Romanian<sup>297</sup> infants and children. Initiation of a national immunization<sup>298</sup> program is urgently needed in order to achieve a reduction in<sup>299</sup> pneumococcal disease in general and of antibiotic-resistant and<sup>300</sup> MDR pneumococcal AOM in particular. <sup>301</sup> Acknowledgements<sup>302</sup> This study was supported by a European Society of Infectious<sup>303</sup> Diseases (ESPID) Research Grant (2010). <sup>304</sup> Conflict of interest: Prof. Ron Dagan has received grants/research<sup>305</sup> support from Berna/Crucell, Pfizer, MSD, and Protea; has been a<sup>306</sup> scientific consultant for GlaxoSmithKline, Pfizer, NASVAX, and<sup>307</sup> MSD and a speaker

for Berna/Crucell, GlaxoSmithKline, and Pfizer; 308 he is a shareholder in Protea/NASVAX. All other authors report no309 conflict of interest.